Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

June 1, 2026

Study Completion Date

November 1, 2027

Conditions

OsteoporosisSpinal Cord Injuries

Interventions

DRUG

Romosozumab

Romosozumab (Amgen Inc., Thousand Oaks, CA) 210mg SQ administered each month

DRUG

Denosumab

Denosumab (Amgen Inc., Thousand Oaks, CA) 60 mg SQ administered every six months

Trial Locations (2)

James J. Peters VA Medical Center, The Bronx

Kessler Institute for Rehabilitation, West Orange

All Listed Sponsors

collaborator

Kessler Institute for Rehabilitation

INDUSTRY

lead

James J. Peters Veterans Affairs Medical Center

FED